Table 7.
Proportion of patients who discontinued and reasons for discontinuation of first‐, second‐ and third‐line therapy; patients with psoriasis initiating new therapy during the registry
| Ustekinumab | Infliximab | Adalimumab | Etanercept | |
|---|---|---|---|---|
| First‐line therapy, N | 361 | 63 | 402 | 289 |
| Number (%) discontinued | 31 (8.6) | 16 (25.4) | 151 (37.6) | 127 (43.9) |
| Reasons for discontinuation | ||||
| Lack of effectiveness | 12 (38.7) | 9 (56.3) | 61 (40.4) | 65 (51.2) |
| Patient choice | 5 (16.1) | ‐ | 38 (25.2) | 16 (12.6) |
| Insurance/reimbursement | 5 (16.1) | 1 (6.3) | 23 (15.2) | 16 (12.6) |
| Other | 4 (12.9) | 1 (6.3) | 25 (16.6) | 23 (18.1) |
| Adverse event | 2 (6.5) | 5 (31.3) | 15 (9.9) | 18.1) |
| Second‐line therapy, N | 566 | 93 | 622 | 155 |
| Number (%) discontinued | 106 (18.7) | 51 (54.8) | 250 (40.2) | 75 (48.4) |
| Reasons for discontinuation | ||||
| Lack of effectiveness | 53 (50.0) | 17 (33.3) | 121 (48.4) | 36 (48.0) |
| Other | 18 (17.0) | 11 (21.6) | 30 (12.0) | 7 (9.3) |
| Patient choice | 16 (15.1) | 3 (5.9) | 33 (13.2) | 12 (16.0) |
| Insurance/reimbursement | 6 (5.7) | 4 (7.8) | 26 (10.4) | 14 (18.7) |
| Adverse event | 4 (3.8) | 14 (27.5) | 25 (10.0) | 8 (10.7) |
| Third‐line therapy, N | 551 | 103 | 197 | 71 |
| Number (%) discontinued | 129 (23.4) | 49 (47.6) | 90 (45.7) | 35 (49.3) |
| Reasons for discontinuation | ||||
| Lack of effectiveness | 73 (56.6) | 25 (51.0) | 46 (51.1) | 24 (68.6) |
| Patient choice | 15 (11.6) | 5 (10.2) | 11 (12.2) | 5 (14.3) |
| Other | 13 (10.1) | 7 (14.3) | 10 (11.1) | 4 (11.4) |
| Insurance/reimbursement | 12 (9.3) | 2 (4.1) | 9 (10.0) | ‐ |
| Adverse event | 6 (4.7) | 8 (16.3) | 8 (8.9) | 3 (8.6) |
Data are listed in ascending order based on first‐line ustekinumab therapy.